Pharma Services & Consumer Health · REVENUE
Commercial Excellence: Proposals, Bids and Retail Plans.
More of the right business at better prices: faster CDMO proposals, disciplined generics bids, and retailer plans for OTC brands built on real margin data.
The problem this solves
- CDMO proposals and quotes that take weeks and lose to faster competitors
- Generics bids and contract prices set without current cost-to-serve
- Trade spend and retailer programs for OTC brands with no measured return
What we measure
- Proposal turnaround and win rate
- Price realization and gross margin by customer
- Trade spend return and retailer service level
Every program starts by baselining these numbers in your systems. Results are reported against your baseline, not against industry averages.
The playbook
01
Proposal and quote engine
Technical and commercial proposals for CDMO opportunities assembled from your capability library, costing models and past work, then reviewed by your business development and technical leads before anything is sent.
02
Bid and price discipline
Bids to wholesaler buying groups, contract renewals and price changes evaluated against current cost-to-serve, capacity and supply risk, with an agreed walk-away price for each.
03
Retail and channel plans
Joint business plans, promotions and e-commerce content for OTC brands, with trade spend measured promotion by promotion. Product claims stay within what your regulatory team has approved.
The market context, in published numbers
89%
of US prescriptions filled in 2025 were generics, which accounted for only 11.6% of total prescription drug spending
Association for Accessible Medicines, 2026 U.S. Generic & Biosimilar Medicines Savings Report (2026)
18%
of the 1,309 drug quality inspections in FDA's FY2025 report (1,248 FDA inspections plus 61 MRA partner inspections) were classified Official Action Indicated (OAI), the most serious outcome; US sites ran higher at 21.6%
12%
of nearly 10,000 FDA applications and supplements needing a facility assessment (received FY2024 to FY2025) got a Complete Response Letter because of facility withholds; FDA lists inadequate investigations and poorly documented quality-unit decisions among the citations behind them
20–50%
potential reduction in forecasting errors from applying AI-driven forecasting to supply chain management
Figures are third-party market benchmarks from the cited sources, not Ometz Partners client results. We share them so you can size the problem before we ever talk.
Capabilities
What the Commercial Growth program covers.
Pricing and margin analytics
Price waterfalls and discount, rebate and mix analysis by customer, product and seller, with escalation and pass-through terms for raw-material, ingredient and freight swings.
Quote, RFP and proposal acceleration
Quote and proposal workflows redesigned, with first drafts assembled automatically from approved content, technical data and pricing guardrails.
Segmentation and coverage
Accounts, distributors, referral sources and prospects segmented by value and potential, with coverage models matched to what each segment is worth.
Inquiry response and qualification
Web, phone, referral and portal inquiries answered quickly, scored against your criteria and routed to the right seller or advisor with context attached.
Targeted demand generation
Outbound, content and search programs aimed at defined segments and buying committees, including visibility when buyers ask AI assistants, measured by qualified pipeline rather than activity.
Cross-sell and retention signals
Early flags on expansion potential and attrition risk from purchasing, service and account data, with a suggested next step for the relationship owner.
Commercial operating rhythm
Pipeline reviews, forecast calls and dashboards on a weekly cadence, built on CRM data your team no longer has to maintain by hand.
Also in the Pharma Services & Consumer Health program
TECHNOLOGY
Quality Documentation Workbench
Cleaner quality records in less time: automation drafts, checks and assembles the documents, your Quality Unit reviews and signs, and release cycle time comes down.
MARGIN
S&OP for SKU-Heavy Portfolios
A planning cycle that holds service levels on less inventory, built for long SKU tails, customer-specific packs and constrained lines.
Next step
Size this opportunity in your own numbers.
The Performance Diagnostic runs for two to four weeks at a fixed fee and ends with a baseline, three priced improvement plays and a 90-day plan. The findings are yours whether or not we continue.